Pivotal Phase 2b clinical trial (ELPIS II) for Lomecel-B™ has achieved over 90% enrollment and is expected to complete enrollment by Q2 2025, indicating strong progress in a rare pediatric disease ...
Children's Hospital Colorado (Children's Colorado) successfully performed the hospital's first-ever heart and liver dual organ transplant, with support from dozens of team members across 25 different ...
BORN WITH AN UNDERDEVELOPED HEART, HAS UNDERGONE TWO OPEN HEART SURGERIES, AND AT THE END OF THE MONTH, HE’LL LEARN IF HE NEEDS A THIRD. YEAH. NEWS EIGHT’S AJ ANNE IS IN LEBANON, INTRODUCING US TO ...
Background Population studies of congenital heart disease (CHD) often include only children receiving cardiac interventions, underestimating the burden of cases without intervention. We evaluated ...
MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (LGVN) (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and ...
ELPIS II top-line trial results are anticipated in the third quarter of 2026 Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results